TrialThe oncologist2025

First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study.

Lijie Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.